The global cell therapy manufacturing market size is expected to reach a valuation of US$ 4,134.48 million in 2023 and further expand at a CAGR of 14.2% from 2023 to 2033. The market is anticipated to reach a valuation of ~US$ 15,634.67 million by the end of 2033. Autologous cell therapy manufacturing is leading the global market and held a share of about 56.0% in 2021.
A sophisticated gene-edited cell-based product such as chimeric antigen receptor (CAR)-T cells or tissue engineering products like Holoclar are examples of modern cell therapies that include but are not limited to blood transfusion and hematopoietic progenitor stem cell transplantation exclusively. Quality standards have evolved in response to the continual improvement of cell therapy manufacturing processes, thereby resulting in improved product consistency, reliability, and efficacy.
Manufacturing processes need a transition from open and manual to closed and automated in order to scale up. This offers several benefits such as decreased risk of contamination, improved product uniformity, increased efficiency, and surging traceability throughout the process to assure the chain of custody.
In order to reduce risks and get ready for a high-production future, groups in both academia and industry are actively implementing novel technologies that help them build automated, scalable, and closed systems. Key players are also working on the development of innovative technologies that assist investigators in automating their processes for success in the future.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
It is challenging and time-consuming for businesses that are not familiar with the cell therapy manufacturing process to build a solid supply chain with the tools and processes required to satisfy consumer demand.
Companies that have a strong understanding of the biology of their product, but are unfamiliar with how to transition from a small, manual production to a scaled-up, automated production that serves the needs of hundreds of thousands of patients globally, quickly bridge the gap with the help of an outside organization, such as a contract manufacturing organization (CMO).
Outsourcing of manufacturing capabilities creates growth opportunities for new industry entrants to scale up their products for wide-scale distribution. Additionally, outsourcing saves manufacturers from making investments in large-scale systems and facilitates anticipation of future product delays or regulatory denials.
Manufacturers of cell therapies face certain process limitations when they aim to provide a functional and safe output from an extremely variable starting material. Increased starting material variability poses limitations on the production protocols for desired end use products.
Additionally, as different phases in the production of cell therapy require variable timespans, bottlenecks develop in a fully automated system by holding one part of equipment engaged for a longer duration of time, while the rest of the system sits idle, not utilizing resources and wasting both time & space.
The design is more efficient in a modular system as only one part of the system is engaged and the rest of the system is available for usage. Another drawback of fully automated systems is that they could bind an organization or a research team to a certain methodology.
| Attributes | Details |
|---|---|
| Cell Therapy Manufacturing Market CAGR (2023 to 2033) | 14.2% |
| Cell Therapy Manufacturing Market Size (2023) | US$ 4,134.48 million |
| Cell Therapy Manufacturing Market Size (2033) | US$ 15,634.67 million |
Principal Consultant
The cell therapy manufacturing industry held approximately 3.3% of the global targeted therapeutics market, which was worth ~US$ 3,685.7 million in 2022. The global cell therapy manufacturing market expanded at a CAGR of 10.7% from 2018 to 2022 owing to the positive outcomes of immunotherapy.
In its most precise definition, cell therapy manufacturing starts with the patient's cell collection in a clinical (or apheresis) facility and ends with the patient receiving the finished drug at their bedside. Numerous hand-off points and activities occur between the initial raw material collection and the subsequent administration of a product.
Cell therapy manufacturing differs from more conventional pharmaceutical production due to the complexity of all these working components in a supply chain, as well as the blend of the production and delivery phases. The majority, if not all, cell therapies currently available are only meant to treat a small number of patients.
However, if they are to be made widely accessible for a variety of indications, advancements in automation, process simplification, and supply chain management are necessary to keep up with the rising demand. Owing to the aforementioned factors, the global market is expected to surge at a CAGR of 14.2% during the forecast period.
The United States dominates the North American region and held a total share of about 42.1% in 2022. The country is expected to continue to remain at the forefront throughout the forecast period. The increasing prevalence of sickle cell disease in the country and the presence of a large number of gene & cell and tissue-based therapeutic developers are likely to drive growth. As per the Centers for Disease Control and Prevention (CDC), sickle cell disease affects nearly 100,000 Americans and it occurs among about 1 out of every 16,300 Hispanic-American births.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The United Kingdom held approximately 26.6% of the Europe market in 2022. The country reflects a lucrative outlook toward cell therapy manufacturing. As per the European Medicines Agency, from 2018 until 2020, nearly 102% of advanced therapy classifications occurred across Europe annually.
China held a share of around 38.2% in 2021 in the East Asia cell therapy manufacturing market, finds FMI. Chinese local biotech businesses are working with industry associations to develop guidelines for maintaining high product quality and introducing new processing methods in an effort to streamline cell therapy manufacturing. China is likely to hold a market CAGR of 22.1% by 2033.
For instance, SALIAI, a leading stem cell start-up, is promoting the establishment of production and quality standards for the stem cell sector while collaborating with the China Quality Association for Pharmaceuticals.
The autologous source segment held the leading share of around 56.0% in 2022. Growth is attributed to various advantages of autologous sources in stem cell transplant. They help in promoting faster recovery of cell counts, reducing mortality rates associated with the treatment modality, and providing a shorter length of hospital stays.
Cancer is expected to showcase high growth at a CAGR of 14.8% by the end of the forecast period. As per FMI, the segment held a market share of about 31.0% in 2022. The high incidence rate of cancer, as well as the growing adoption of novel treatment models for targeted therapy, are propelling the segment in the global cell therapy manufacturing market.
For pre-clinical, clinical, and commercial scaling of cell therapy products, manufacturing processes promote adoptive standardization for each protocol. Clinical manufacturing held a high market share of around 42.0% in the global market, followed by commercial manufacturing, which accounted for a share of about 32.0% globally in 2022.
Injectables held a market share of about 44.0% in 2022 in the global market. Injectables promote greater absorption of therapeutic drugs at the target site and hence contribute to a positive outcome for disease treatment. Moreover, injections for cell therapy exhibit better cell retention at the targeted site of the disease.
The hematopoietic stem cells (HSC) segment held a share of around 25.0% in 2022 in the cell therapy manufacturing market as many malignant disorders, including leukemia and lymphoma, as well as non-malignant conditions such as sickle cell disease, are treated with HSCs in order to replace or rebuild the patient's hematopoietic system.
Hospital settings held the leading market share of around 38.1% in 2022, says FMI. This segment is emerging as a valuable end user with the advancement of point-of-care manufacturing of cell therapies in units close to hospital settings for increased accessibility of treatment, as well as to reduce treatment time and risk of contamination.
Competitive Landscape
The global cell therapy manufacturing market is fragmented with the presence of a large number of companies. They are striving persistently to build digital capabilities for cell therapy production. These efforts help them to optimize their business processes and expand their portfolios in the global market.
For instance,
Key players
The cell therapy manufacturing sector expanded at a share of US$ 3,685.79 million in 2022.
The United States is set to register exponential growth in the cell therapy manufacturing market.
The increasing demand for cell therapy products and the growing number of clinical trials are expected to drive cell therapy manufacturing sales.
The rising adoption of automation and the increasing focus on personalized medicine are key trends driving the cell therapy manufacturing market.
Substantial investment in research and development and expansion into new markets are expected to provide growth prospects for the market players.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Source
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Source, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Source, 2023 to 2033
5.3.1. Autologous
5.3.2. Allogenic
5.4. Y-o-Y Growth Trend Analysis By Source, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Source, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
6.3.1. HIV
6.3.2. Autoimmune Disorders
6.3.3. Immune Deficiencies
6.3.4. Cancer
6.3.5. Neurological Disorders
6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Manufacturing Purpose
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Manufacturing Purpose, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Manufacturing Purpose, 2023 to 2033
7.3.1. Clinical
7.3.2. Commercial
7.3.3. Pre-clinical
7.4. Y-o-Y Growth Trend Analysis By Manufacturing Purpose, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Manufacturing Purpose, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
8.3.1. Topical
8.3.2. Injectable
8.3.3. Infusion
8.3.4. Implantable Bio-Scaffold
8.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cell Type
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By Cell Type, 2018 to 2022
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Cell Type, 2023 to 2033
9.3.1. Hematopoietic (Blood-Forming) Stem Cells (HSC)
9.3.2. Skeletal Muscle Stem Cells
9.3.3. Mesenchymal Stem Cells
9.3.4. Lymphocytes
9.3.5. Dendritic Cells
9.3.6. Pancreatic Islet Cells
9.3.7. CAR-T Cells
9.4. Y-o-Y Growth Trend Analysis By Cell Type, 2018 to 2022
9.5. Absolute $ Opportunity Analysis By Cell Type, 2023 to 2033
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
10.1. Introduction / Key Findings
10.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
10.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
10.3.1. Hospital Settings
10.3.2. Intensive Outpatient Treatment Centers
10.3.3. Academic and Research Institutes
10.3.4. Specialty Clinics
10.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
10.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
11.1. Introduction
11.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
11.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Western Europe
11.3.4. Eastern Europe
11.3.5. South Asia and Pacific
11.3.6. East Asia
11.3.7. Middle East and Africa
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. U.S.
12.2.1.2. Canada
12.2.2. By Source
12.2.3. By Indication
12.2.4. By Manufacturing Purpose
12.2.5. By Route of Administration
12.2.6. By Cell Type
12.2.7. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Source
12.3.3. By Indication
12.3.4. By Manufacturing Purpose
12.3.5. By Route of Administration
12.3.6. By Cell Type
12.3.7. By End User
12.4. Key Takeaways
13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Brazil
13.2.1.2. Mexico
13.2.1.3. Rest of Latin America
13.2.2. By Source
13.2.3. By Indication
13.2.4. By Manufacturing Purpose
13.2.5. By Route of Administration
13.2.6. By Cell Type
13.2.7. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Source
13.3.3. By Indication
13.3.4. By Manufacturing Purpose
13.3.5. By Route of Administration
13.3.6. By Cell Type
13.3.7. By End User
13.4. Key Takeaways
14. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Germany
14.2.1.2. U.K.
14.2.1.3. France
14.2.1.4. Spain
14.2.1.5. Italy
14.2.1.6. Rest of Western Europe
14.2.2. By Source
14.2.3. By Indication
14.2.4. By Manufacturing Purpose
14.2.5. By Route of Administration
14.2.6. By Cell Type
14.2.7. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Source
14.3.3. By Indication
14.3.4. By Manufacturing Purpose
14.3.5. By Route of Administration
14.3.6. By Cell Type
14.3.7. By End User
14.4. Key Takeaways
15. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Poland
15.2.1.2. Russia
15.2.1.3. Czech Republic
15.2.1.4. Romania
15.2.1.5. Rest of Eastern Europe
15.2.2. By Source
15.2.3. By Indication
15.2.4. By Manufacturing Purpose
15.2.5. By Route of Administration
15.2.6. By Cell Type
15.2.7. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Source
15.3.3. By Indication
15.3.4. By Manufacturing Purpose
15.3.5. By Route of Administration
15.3.6. By Cell Type
15.3.7. By End User
15.4. Key Takeaways
16. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. India
16.2.1.2. Bangladesh
16.2.1.3. Australia
16.2.1.4. New Zealand
16.2.1.5. Rest of South Asia and Pacific
16.2.2. By Source
16.2.3. By Indication
16.2.4. By Manufacturing Purpose
16.2.5. By Route of Administration
16.2.6. By Cell Type
16.2.7. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Source
16.3.3. By Indication
16.3.4. By Manufacturing Purpose
16.3.5. By Route of Administration
16.3.6. By Cell Type
16.3.7. By End User
16.4. Key Takeaways
17. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
17.2.1. By Country
17.2.1.1. China
17.2.1.2. Japan
17.2.1.3. South Korea
17.2.2. By Source
17.2.3. By Indication
17.2.4. By Manufacturing Purpose
17.2.5. By Route of Administration
17.2.6. By Cell Type
17.2.7. By End User
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Source
17.3.3. By Indication
17.3.4. By Manufacturing Purpose
17.3.5. By Route of Administration
17.3.6. By Cell Type
17.3.7. By End User
17.4. Key Takeaways
18. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
18.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
18.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
18.2.1. By Country
18.2.1.1. GCC Countries
18.2.1.2. South Africa
18.2.1.3. Israel
18.2.1.4. Rest of MEA
18.2.2. By Source
18.2.3. By Indication
18.2.4. By Manufacturing Purpose
18.2.5. By Route of Administration
18.2.6. By Cell Type
18.2.7. By End User
18.3. Market Attractiveness Analysis
18.3.1. By Country
18.3.2. By Source
18.3.3. By Indication
18.3.4. By Manufacturing Purpose
18.3.5. By Route of Administration
18.3.6. By Cell Type
18.3.7. By End User
18.4. Key Takeaways
19. Key Countries Market Analysis
19.1. USA
19.1.1. Pricing Analysis
19.1.2. Market Share Analysis, 2022
19.1.2.1. By Source
19.1.2.2. By Indication
19.1.2.3. By Manufacturing Purpose
19.1.2.4. By Route of Administration
19.1.2.5. By Cell Type
19.1.2.6. By End User
19.2. Canada
19.2.1. Pricing Analysis
19.2.2. Market Share Analysis, 2022
19.2.2.1. By Source
19.2.2.2. By Indication
19.2.2.3. By Manufacturing Purpose
19.2.2.4. By Route of Administration
19.2.2.5. By Cell Type
19.2.2.6. By End User
19.3. Brazil
19.3.1. Pricing Analysis
19.3.2. Market Share Analysis, 2022
19.3.2.1. By Source
19.3.2.2. By Indication
19.3.2.3. By Manufacturing Purpose
19.3.2.4. By Route of Administration
19.3.2.5. By Cell Type
19.3.2.6. By End User
19.4. Mexico
19.4.1. Pricing Analysis
19.4.2. Market Share Analysis, 2022
19.4.2.1. By Source
19.4.2.2. By Indication
19.4.2.3. By Manufacturing Purpose
19.4.2.4. By Route of Administration
19.4.2.5. By Cell Type
19.4.2.6. By End User
19.5. Germany
19.5.1. Pricing Analysis
19.5.2. Market Share Analysis, 2022
19.5.2.1. By Source
19.5.2.2. By Indication
19.5.2.3. By Manufacturing Purpose
19.5.2.4. By Route of Administration
19.5.2.5. By Cell Type
19.5.2.6. By End User
19.6. UK
19.6.1. Pricing Analysis
19.6.2. Market Share Analysis, 2022
19.6.2.1. By Source
19.6.2.2. By Indication
19.6.2.3. By Manufacturing Purpose
19.6.2.4. By Route of Administration
19.6.2.5. By Cell Type
19.6.2.6. By End User
19.7. France
19.7.1. Pricing Analysis
19.7.2. Market Share Analysis, 2022
19.7.2.1. By Source
19.7.2.2. By Indication
19.7.2.3. By Manufacturing Purpose
19.7.2.4. By Route of Administration
19.7.2.5. By Cell Type
19.7.2.6. By End User
19.8. Spain
19.8.1. Pricing Analysis
19.8.2. Market Share Analysis, 2022
19.8.2.1. By Source
19.8.2.2. By Indication
19.8.2.3. By Manufacturing Purpose
19.8.2.4. By Route of Administration
19.8.2.5. By Cell Type
19.8.2.6. By End User
19.9. Italy
19.9.1. Pricing Analysis
19.9.2. Market Share Analysis, 2022
19.9.2.1. By Source
19.9.2.2. By Indication
19.9.2.3. By Manufacturing Purpose
19.9.2.4. By Route of Administration
19.9.2.5. By Cell Type
19.9.2.6. By End User
19.10. Poland
19.10.1. Pricing Analysis
19.10.2. Market Share Analysis, 2022
19.10.2.1. By Source
19.10.2.2. By Indication
19.10.2.3. By Manufacturing Purpose
19.10.2.4. By Route of Administration
19.10.2.5. By Cell Type
19.10.2.6. By End User
19.11. Russia
19.11.1. Pricing Analysis
19.11.2. Market Share Analysis, 2022
19.11.2.1. By Source
19.11.2.2. By Indication
19.11.2.3. By Manufacturing Purpose
19.11.2.4. By Route of Administration
19.11.2.5. By Cell Type
19.11.2.6. By End User
19.12. Czech Republic
19.12.1. Pricing Analysis
19.12.2. Market Share Analysis, 2022
19.12.2.1. By Source
19.12.2.2. By Indication
19.12.2.3. By Manufacturing Purpose
19.12.2.4. By Route of Administration
19.12.2.5. By Cell Type
19.12.2.6. By End User
19.13. Romania
19.13.1. Pricing Analysis
19.13.2. Market Share Analysis, 2022
19.13.2.1. By Source
19.13.2.2. By Indication
19.13.2.3. By Manufacturing Purpose
19.13.2.4. By Route of Administration
19.13.2.5. By Cell Type
19.13.2.6. By End User
19.14. India
19.14.1. Pricing Analysis
19.14.2. Market Share Analysis, 2022
19.14.2.1. By Source
19.14.2.2. By Indication
19.14.2.3. By Manufacturing Purpose
19.14.2.4. By Route of Administration
19.14.2.5. By Cell Type
19.14.2.6. By End User
19.15. Bangladesh
19.15.1. Pricing Analysis
19.15.2. Market Share Analysis, 2022
19.15.2.1. By Source
19.15.2.2. By Indication
19.15.2.3. By Manufacturing Purpose
19.15.2.4. By Route of Administration
19.15.2.5. By Cell Type
19.15.2.6. By End User
19.16. Australia
19.16.1. Pricing Analysis
19.16.2. Market Share Analysis, 2022
19.16.2.1. By Source
19.16.2.2. By Indication
19.16.2.3. By Manufacturing Purpose
19.16.2.4. By Route of Administration
19.16.2.5. By Cell Type
19.16.2.6. By End User
19.17. New Zealand
19.17.1. Pricing Analysis
19.17.2. Market Share Analysis, 2022
19.17.2.1. By Source
19.17.2.2. By Indication
19.17.2.3. By Manufacturing Purpose
19.17.2.4. By Route of Administration
19.17.2.5. By Cell Type
19.17.2.6. By End User
19.18. China
19.18.1. Pricing Analysis
19.18.2. Market Share Analysis, 2022
19.18.2.1. By Source
19.18.2.2. By Indication
19.18.2.3. By Manufacturing Purpose
19.18.2.4. By Route of Administration
19.18.2.5. By Cell Type
19.18.2.6. By End User
19.19. Japan
19.19.1. Pricing Analysis
19.19.2. Market Share Analysis, 2022
19.19.2.1. By Source
19.19.2.2. By Indication
19.19.2.3. By Manufacturing Purpose
19.19.2.4. By Route of Administration
19.19.2.5. By Cell Type
19.19.2.6. By End User
19.20. South Korea
19.20.1. Pricing Analysis
19.20.2. Market Share Analysis, 2022
19.20.2.1. By Source
19.20.2.2. By Indication
19.20.2.3. By Manufacturing Purpose
19.20.2.4. By Route of Administration
19.20.2.5. By Cell Type
19.20.2.6. By End User
19.21. GCC Countries
19.21.1. Pricing Analysis
19.21.2. Market Share Analysis, 2022
19.21.2.1. By Source
19.21.2.2. By Indication
19.21.2.3. By Manufacturing Purpose
19.21.2.4. By Route of Administration
19.21.2.5. By Cell Type
19.21.2.6. By End User
19.22. South Africa
19.22.1. Pricing Analysis
19.22.2. Market Share Analysis, 2022
19.22.2.1. By Source
19.22.2.2. By Indication
19.22.2.3. By Manufacturing Purpose
19.22.2.4. By Route of Administration
19.22.2.5. By Cell Type
19.22.2.6. By End User
19.23. Israel
19.23.1. Pricing Analysis
19.23.2. Market Share Analysis, 2022
19.23.2.1. By Source
19.23.2.2. By Indication
19.23.2.3. By Manufacturing Purpose
19.23.2.4. By Route of Administration
19.23.2.5. By Cell Type
19.23.2.6. By End User
20. Market Structure Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Market Share Analysis of Top Players
20.3.1. By Regional
20.3.2. By Source
20.3.3. By Indication
20.3.4. By Manufacturing Purpose
20.3.5. By Route of Administration
20.3.6. By Cell Type
20.3.7. By End User
21. Competition Analysis
21.1. Competition Deep Dive
21.1.1. Merck KGaA
21.1.1.1. Overview
21.1.1.2. Product Portfolio
21.1.1.3. Profitability by Market Segments
21.1.1.4. Sales Footprint
21.1.1.5. Strategy Overview
21.1.1.5.1. Marketing Strategy
21.1.2. Avantor, Inc.
21.1.2.1. Overview
21.1.2.2. Product Portfolio
21.1.2.3. Profitability by Market Segments
21.1.2.4. Sales Footprint
21.1.2.5. Strategy Overview
21.1.2.5.1. Marketing Strategy
21.1.3. Cell Therapies Pty Ltd
21.1.3.1. Overview
21.1.3.2. Product Portfolio
21.1.3.3. Profitability by Market Segments
21.1.3.4. Sales Footprint
21.1.3.5. Strategy Overview
21.1.3.5.1. Marketing Strategy
21.1.4. Thermo Fisher Scientific
21.1.4.1. Overview
21.1.4.2. Product Portfolio
21.1.4.3. Profitability by Market Segments
21.1.4.4. Sales Footprint
21.1.4.5. Strategy Overview
21.1.4.5.1. Marketing Strategy
21.1.5. Charles River Laboratories
21.1.5.1. Overview
21.1.5.2. Product Portfolio
21.1.5.3. Profitability by Market Segments
21.1.5.4. Sales Footprint
21.1.5.5. Strategy Overview
21.1.5.5.1. Marketing Strategy
21.1.6. Catalent, Inc
21.1.6.1. Overview
21.1.6.2. Product Portfolio
21.1.6.3. Profitability by Market Segments
21.1.6.4. Sales Footprint
21.1.6.5. Strategy Overview
21.1.6.5.1. Marketing Strategy
21.1.7. Bio-Techne
21.1.7.1. Overview
21.1.7.2. Product Portfolio
21.1.7.3. Profitability by Market Segments
21.1.7.4. Sales Footprint
21.1.7.5. Strategy Overview
21.1.7.5.1. Marketing Strategy
21.1.8. Cytiva
21.1.8.1. Overview
21.1.8.2. Product Portfolio
21.1.8.3. Profitability by Market Segments
21.1.8.4. Sales Footprint
21.1.8.5. Strategy Overview
21.1.8.5.1. Marketing Strategy
21.1.9. Lonza
21.1.9.1. Overview
21.1.9.2. Product Portfolio
21.1.9.3. Profitability by Market Segments
21.1.9.4. Sales Footprint
21.1.9.5. Strategy Overview
21.1.9.5.1. Marketing Strategy
21.1.10. The Discovery Labs
21.1.10.1. Overview
21.1.10.2. Product Portfolio
21.1.10.3. Profitability by Market Segments
21.1.10.4. Sales Footprint
21.1.10.5. Strategy Overview
21.1.10.5.1. Marketing Strategy
21.1.11. BIOCENTRIQ
21.1.11.1. Overview
21.1.11.2. Product Portfolio
21.1.11.3. Profitability by Market Segments
21.1.11.4. Sales Footprint
21.1.11.5. Strategy Overview
21.1.11.5.1. Marketing Strategy
21.1.12. FUJIFILM Diosynth Biotechnologies
21.1.12.1. Overview
21.1.12.2. Product Portfolio
21.1.12.3. Profitability by Market Segments
21.1.12.4. Sales Footprint
21.1.12.5. Strategy Overview
21.1.12.5.1. Marketing Strategy
21.1.13. Novartis AG
21.1.13.1. Overview
21.1.13.2. Product Portfolio
21.1.13.3. Profitability by Market Segments
21.1.13.4. Sales Footprint
21.1.13.5. Strategy Overview
21.1.13.5.1. Marketing Strategy
21.1.14. Bristol-Myers Squibb Company
21.1.14.1. Overview
21.1.14.2. Product Portfolio
21.1.14.3. Profitability by Market Segments
21.1.14.4. Sales Footprint
21.1.14.5. Strategy Overview
21.1.14.5.1. Marketing Strategy
21.1.15. Gilead Sciences, Inc.
21.1.15.1. Overview
21.1.15.2. Product Portfolio
21.1.15.3. Profitability by Market Segments
21.1.15.4. Sales Footprint
21.1.15.5. Strategy Overview
21.1.15.5.1. Marketing Strategy
21.1.16. WuXi AppTec.
21.1.16.1. Overview
21.1.16.2. Product Portfolio
21.1.16.3. Profitability by Market Segments
21.1.16.4. Sales Footprint
21.1.16.5. Strategy Overview
21.1.16.5.1. Marketing Strategy
21.1.17. OXGENE
21.1.17.1. Overview
21.1.17.2. Product Portfolio
21.1.17.3. Profitability by Market Segments
21.1.17.4. Sales Footprint
21.1.17.5. Strategy Overview
21.1.17.5.1. Marketing Strategy
21.1.18. Pharmaron
21.1.18.1. Overview
21.1.18.2. Product Portfolio
21.1.18.3. Profitability by Market Segments
21.1.18.4. Sales Footprint
21.1.18.5. Strategy Overview
21.1.18.5.1. Marketing Strategy
21.1.19. Aldevron
21.1.19.1. Overview
21.1.19.2. Product Portfolio
21.1.19.3. Profitability by Market Segments
21.1.19.4. Sales Footprint
21.1.19.5. Strategy Overview
21.1.19.5.1. Marketing Strategy
21.1.20. FLODESIGN SONICS
21.1.20.1. Overview
21.1.20.2. Product Portfolio
21.1.20.3. Profitability by Market Segments
21.1.20.4. Sales Footprint
21.1.20.5. Strategy Overview
21.1.20.5.1. Marketing Strategy
22. Assumptions & Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Cell Therapy Manufacturing Market
